|
Ragaglitazar
story - some thoughts
It was extremely disappointing to read that Novo Nordisk has
decided to suspend the clinical development of Dr Reddy’s Laboratories
PPAR-gamma and PPAR-alpha dual acting insulin sensitizer Ragaglitazar
(DRF 2725) which Reddy’s Labs (DRL) had out-licenced to Novo
Nordisk in 1997, due to the emergence of bladder tumours in one
mouse and several rats treated with Ragaglitazar in development
studies.
Rodent
studies not commenced late: Novo
The Danish diabetes major Novo Nordisk strongly refuted the
allegations that the company has not acted appropriately in connection
with the ragaglitazar clinical trials.
|
